PFE

Pfizer Inc.

Healthcare
25.34 -0.22 -0.86% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 144.42B
EV —
Shares Out 5.70B
Revenue (ttm) 63.31B
Net Income 7.49B
Beta —
P/E 19.25
Forward P/E —
EPS (ttm) $1.31
P/S 2.28
P/B 1.60
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 3.61%
ROE 8.36%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 11.83%
Debt/Eq 0.76
LT Debt/Eq 40.2%
Quick Ratio —
Current Ratio 1.25
Book/sh 15.83
Cash/sh 0.3
Div Yield 11.52%
Div TTM $2.92
Payout Ratio 222.9%
SMA20 -1.96%
SMA50 -4.89%
SMA200 -1.93%
Volume 30,957,066
Avg Volume 40.10M
Rel Volume —
Perf Week -3.17%
Perf Month -4.20%
Perf Quarter -4.77%
Perf Half Y -2.65%
Perf YTD 1.77%
Perf Year 9.60%
Perf 3Y -34.44%
Perf 5Y -35.27%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.8600
TTM Yield 11.52%
TTM Amount $2.92
Payout Ratio 222.9%
3-Yr Growth (CAGR) —
5-Yr Growth (CAGR) —

Last 12 Payouts

Period Ex-Date Amount / Share
Q2 2025 ~2025-06-29 $0.8600
Q2 2024 ~2024-06-30 $0.8400
Q2 2023 ~2023-07-02 $0.8200
Q3 2022 ~2022-10-02 $0.4000
Q2 2022 ~2022-07-03 $0.8000
Q3 2021 ~2021-10-03 $0.3900
Q2 2021 ~2021-07-04 $0.7800
Q3 2020 ~2020-09-27 $0.3800
Q3 2020 ~2020-09-24 $0.3800
Q2 2020 ~2020-06-28 $0.7600
Q2 2020 ~2020-06-25 $0.3800
Q2 2020 ~2020-04-23 $0.3800

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We manage our commercial operations through a global structure consisting of three operating segments: Biopharma (our innovative science-based biopharmaceutical business engaged in discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide), PC1 (our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients), and Pfizer Ignite (an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies, which is being discontinued). Our R&D priorities focus on oncology, internal medicine (including cardiometabolic, weight management and migraine), vaccines (with a pipeline focus on infectious diseases with significant unmet medical need) and inflammation and immunology.

Name
Pfizer Inc.
Industry
Drug Manufacturers - General
CEO
Albert Bourla · Chairman and Chief Executive Officer
Employees
75,000 as of 2025-12-31
IPO Date
2020-12-02
Phone
(212) 733-2323
Address
66 Hudson Boulevard East, New York, NY 10001-2192
Website
www.pfizer.com

Key Executives

Name Title FY Pay
Douglas M. Lankler Chief Legal Officer, Executive Vice President —
Aamir Malik Chief U.S. Commercial Officer, Executive Vice President —
Chris Boshoff Chief Scientific Officer and President, Research & Development —
David M. Denton Chief Financial Officer, Executive Vice President —
Albert Bourla Chairman and Chief Executive Officer —

Latest News